Search
Products
Community
Markets
News
Brokers
More
IN
Get started
Markets
/
/
Financials
C
Contineum Therapeutics, Inc.
CTNM
Nasdaq Stock Market
CTNM
Nasdaq Stock Market
CTNM
Nasdaq Stock Market
CTNM
Nasdaq Stock Market
Market open
Market open
14.15
USD
R
+0.09
+0.64%
As of today at 15:11 UTC
USD
No trades
See on Supercharts
Overview
Financials
News
Discussions
Technicals
Forecast
Seasonals
CTNM fundamentals
Overview
Statements
Statistics
Dividends
Earnings
Revenue
More
Contineum Therapeutics, Inc. financial statements, including revenue, expenses, profit, and loss
The annual and quarterly earnings report below will help you understand the performance of CTNM.
Q4 '22
Q1 '23
Q2 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
−17.00 M
0.00
17.00 M
34.00 M
51.00 M
Total revenue
Gross profit
Operating income
Pretax income
Net income
Income statement
Balance sheet
Cash flow
Annual
Annual
Quarterly
Quarterly
More
More
Currency: USD
Q4 '22
Dec 2022
Q1 '23
Mar 2023
Q2 '23
Jun 2023
Q4 '23
Dec 2023
Q1 '24
Mar 2024
Q2 '24
Jun 2024
Q3 '24
Sep 2024
TTM
Total revenue
YoY growth
0.00
—
0.00
—
50.00 M
—
0.00
—
0.00
—
0.00
—
0.00
−100.00%
—
Cost of goods sold
−81.00 K
−73.00 K
−42.00 K
−37.00 K
−61.00 K
−60.00 K
−62.00 K
−220.00 K
Gross profit
YoY growth
−81.00 K
—
−73.00 K
—
49.96 M
—
−37.00 K
—
−61.00 K
+24.69%
−60.00 K
+17.81%
−62.00 K
−100.12%
−220.00 K
Operating expenses (excl. COGS)
−5.37 M
−5.04 M
−11.02 M
−9.64 M
−9.87 M
−10.88 M
−12.91 M
−43.30 M
Operating income
YoY growth
−5.45 M
—
−5.12 M
—
38.94 M
—
−9.68 M
—
−9.93 M
−82.24%
−10.94 M
−113.96%
−12.97 M
−133.32%
−43.52 M
Non-operating income, total
−2.06 M
291.00 K
3.36 M
1.75 M
1.51 M
1.93 M
2.71 M
7.90 M
Pretax income
YoY growth
−7.51 M
—
−4.82 M
—
42.29 M
—
−7.93 M
—
−8.42 M
−12.05%
−9.01 M
−86.75%
−10.27 M
−124.28%
−35.62 M
Equity in earnings
0.00
0.00
0.00
0.00
0.00
0.00
0.00
—
Taxes
0.00
0.00
−729.00 K
161.00 K
0.00
0.00
0.00
161.00 K
Non-controlling/minority interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
—
After tax other income/expense
0.00
0.00
0.00
0.00
0.00
0.00
0.00
—
Net income before discontinued operations
−7.51 M
−4.82 M
41.56 M
−7.77 M
−8.42 M
−9.01 M
−10.27 M
−35.46 M
Discontinued operations
0.00
0.00
0.00
0.00
0.00
0.00
0.00
—
Net income
YoY growth
−7.51 M
—
−4.82 M
—
41.56 M
—
−7.77 M
—
−8.42 M
−12.05%
−9.01 M
−86.75%
−10.27 M
−124.70%
−35.46 M
Dilution adjustment
0.00
0.00
0.00
0.00
0.00
0.00
0.00
—
Preferred dividends
0.00
0.00
0.00
−6.58 M
0.00
0.00
0.00
−6.58 M
Diluted net income available to common stockholders
−7.51 M
−4.82 M
41.56 M
−1.19 M
−8.42 M
−9.01 M
−10.27 M
−28.89 M
Basic earnings per share (Basic EPS)
YoY growth
−0.30
—
−0.19
—
1.62
—
−0.05
—
−0.33
−9.47%
−0.35
−86.77%
−0.40
−124.69%
−1.12
Diluted earnings per share (Diluted EPS)
YoY growth
−0.30
—
−0.19
—
1.62
—
−0.05
—
−0.33
−9.47%
−0.35
−86.77%
−0.40
−124.69%
−1.12
Average basic shares outstanding
25.13 M
25.72 M
25.72 M
25.13 M
25.72 M
25.72 M
25.74 M
—
Diluted shares outstanding
25.13 M
25.72 M
25.72 M
25.13 M
25.72 M
25.72 M
25.74 M
—
EBITDA
YoY growth
−5.37 M
—
−5.04 M
—
38.98 M
—
−9.64 M
—
−9.87 M
−83.85%
−10.88 M
−115.87%
−12.91 M
−133.13%
−43.30 M
EBIT
YoY growth
−5.45 M
—
−5.12 M
—
38.94 M
—
−9.68 M
—
−9.93 M
−82.24%
−10.94 M
−113.96%
−12.97 M
−133.32%
−43.52 M
Total operating expenses
−5.45 M
−5.12 M
−11.06 M
−9.68 M
−9.93 M
−10.94 M
−12.97 M
−43.52 M